Announcements
Projects
Orgs
Project Post
Articles 81
Votes 1
0% interested
Targetedonc.com

Authors 48

Conor Killmurray
Alan Bryce
MD
Eleni Efstathiou
Daniel Landau
Adam Weiner
William J. Gradishar
Tony Berberabe
MPH
Jordyn Sava
Naveen Pemmaraju
Ariana Pelosci
Kristie L. Kahl
Cristian Tomasetti
PhD
Aditya Bardia
Nichole Tucker
Targeted Oncology Staff
Lisa Astor
John E. Sylvester
Dylann Cohn-Emery
Luis E. Raez
John M. Burke
Lauren Bollinger
Russ Conroy
Laura Dawson
Kristi Rosa
David O'Malley
Nicholas J. Robert
Bruno Lemos
Jennifer Gass
FACMG
Jonah Feldman
Skye Montoya
Tara Seery
Ritu Salani
Chad A. Hamilton
Pallawi Torka
Crystal Ritchey
Naomi G. Dempsey
Ruchi Garg
Morgan Bayer
Sabrina Serani
Mark A. Davis
MS
Joshua Richter
Nasir Chaudry
Sara A. Hurvitz
Circulating Tumor DNA Measurement in Lymphoma One of the Big Stories From ASH - Targeted Oncology
>2y
Cervical Cancer Awareness Month: Dramatic Increase in Cervical Cancer Research Is Driving Treatment Progress - Targeted Oncology
>2y
FDA Grants Fast Track Designation to Novel TKK1 Therapy for ER+/HER2- Advanced Breast Cancer - Targeted Oncology
>2y
Sotorasib Reveals Anti-Tumor Efficacy in KRAS G12C-Positive Advanced Pancreatic Cancer - Targeted Oncology
>2y
Discussing Updates in the Management of Patients With Metastatic Melanoma - Targeted Oncology
>2y
Individualized Care to Prevent Overtreatment and Undertreatment in Thyroid Cancer - Targeted Oncology
>2y
Importance of Molecular Imaging in Patients With Prostate Cancer - Targeted Oncology
>2y
Realizing the Promise of Biomarker Testing in Lung Cancer and Beyond - Targeted Oncology
>2y
Clinical Commentary: Sharma Shows How Sacituzumab Impacts Treatment for Patients With TNBC - Targeted Oncology
>2y
Promising Efficacy Seen With Lintuzumab-Ac225/Chemotherapy in R/R AML - Targeted Oncology
>2y
Early Detection & the Right Treatment Critical for Prostate Cancer - Targeted Oncology
>2y
Safety of Tucatinib Triplet for HER2+ Breast Cancer Sealed in Real-World Analysis - Targeted Oncology
>2y
Updates Results Support Repotrectinib in ROS1+ NSCLC - Targeted Oncology
>2y
Roundtable Discussion: Savvides Analyzes Role of Hedgehog Inhibitors and Immunotherapy in BCC - Targeted Oncology
>2y
Achieving EFS After 2 Years Shows Signs of Promising OS in MCL - Targeted Oncology
>2y
Trilaciclib Shows Potential to Lower Chemotherapy-Induced Myelosuppression Episodes in ES-SCLC - Targeted Oncology
>2y
Biomarker Testing in Patients With ER+/HER2- mBC - Targeted Oncology
>2y
Using ctDNA in Stage II Colon Cancer - Targeted Oncology
>2y
Withholding RAI Therapy in Low-Risk Pediatric DTC Continues to Yield Comparable Remission Rates - Targeted Oncology
>2y
Brentuximab Vedotin Shows Promising Activity as First-Line Use in Classical Hodgkin Lymphoma - Targeted Oncology
>2y
Update Shows Long-Term Benefits of Tagraxofusp in BPDCN - Targeted Oncology
almost3y
Novel Peptide Based Vaccine Demonstrates Safe in Advanced NSCLC - Targeted Oncology
almost3y
Duration of Response With Xevinapant Plus Standard Chemoradiation in LA SCCHN - Targeted Oncology
almost3y
Immune Checkpoint Inhibitors and Novel Agents Are Explored in Hodgkin Lymphoma - Targeted Oncology
almost3y
Emerging Biomarkers Inform Therapy Choice in HR+ Breast Cancer - Targeted Oncology
almost3y